Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease

[1]  G. Clines,et al.  Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. , 2005, Endocrine-related cancer.

[2]  L. Rao,et al.  Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands. , 2005, Endocrine reviews.

[3]  J. Damber.  Endocrine therapy for prostate cancer , 2005, Acta oncologica.

[4]  Mai-Szu Wu,et al.  Hypercalcemia in Prostate Cancer with Positive Neuron‐Specific Enolase Stain , 2004, Renal failure.

[5]  P. Kantoff,et al.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Rastad,et al.  Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. , 2002, The Journal of clinical endocrinology and metabolism.

[7]  L. Dogliotti,et al.  Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases. , 2002, The International journal of biological markers.

[8]  Kevin Regan,et al.  Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Mundy.  Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.

[10]  L. Dogliotti,et al.  Hyperparathyroidism due to the so-called bone hunger syndrome in prostate cancer patients. , 2002, The Journal of clinical endocrinology and metabolism.

[11]  J. Bilezikian.  Sex Steroids, Mice, and Men: When Androgens and Estrogens Get Very Close to Each Other , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  L. Dogliotti,et al.  Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. , 2001, The Journal of urology.

[13]  P. Pitt,et al.  Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. , 2001, The Journal of clinical endocrinology and metabolism.

[14]  L. Dogliotti,et al.  Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. , 2000, The Journal of urology.

[15]  K. O̸lgaard,et al.  PTHrP enhances the secretory response of PTH to a hypocalcemic stimulus in rat parathyroid glands. , 2000, Kidney international.

[16]  R. De Angelis,et al.  Estimating Relative Survival of Italian Cancer Patients from Sparse Cancer Registries Data , 1997, Tumori.

[17]  Zuxiong Chen,et al.  Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. , 1996, The Journal of urology.

[18]  P. di Sant'Agnese,et al.  Parathyroid hormone-related protein is expressed by prostatic neuroendocrine cells. , 1994, Urology.

[19]  R. Vassilopoulou-sellin,et al.  Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center , 1993, Cancer.

[20]  D. Smith,et al.  Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Ralston,et al.  Cancer-Associated Hypercalcemia: Morbidity and Mortality: Clinical Experience in 126 Treated Patients , 1990 .

[22]  L. Deftos.  Granin‐A, parathyroid hormone‐related protein, and calcitonin gene products in neuroendocrine prostate cancer , 1998, The Prostate. Supplement.